Stock listing

NASDAQ:VBIO Valion Bio, Inc. Stock

Home listing (NASDAQ) of Valion Bio, Inc.

Follow Valion Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:VBIO

$0.481 USD -0.022 (-4.3%)

Close on Nov 20, 2026

Past year -98.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.480 – $0.547 USDNov 20, 2026
Volume
135,203 sharesNov 20, 2026
Market cap
$1.04M USDAt the close on Nov 20, 2026 · price × 2.16M shares outstanding
52-week range
$0.473 – $67.500 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.73M USDMedian day 139,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Valion Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:VBIO · Home$0.481 USD-0.022 (-4.3%)135,203$0.540$0.547$0.480$0.502Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VBIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.481-0.022-4.3%$0.540$0.547$0.480135,203
$0.502-0.041-7.5%$0.559$0.559$0.484105,521
$0.543+0.014+2.7%$0.562$0.598$0.5001,188,067
$0.5290.000-0.1%$0.540$0.540$0.505114,483
$0.529+0.021+4.1%$0.492$0.548$0.480100,089
$0.509+0.006+1.2%$0.507$0.516$0.49182,648
$0.503-0.026-4.9%$0.523$0.536$0.49358,767
$0.529-0.013-2.3%$0.545$0.545$0.50146,850
$0.542+0.032+6.2%$0.510$0.568$0.510118,023
$0.510+0.008+1.6%$0.488$0.510$0.48199,173
$0.502-0.015-2.9%$0.520$0.520$0.473111,521
$0.517-0.014-2.6%$0.540$0.540$0.50093,037
$0.5310.0000.0%$0.530$0.563$0.50555,898
$0.531-0.019-3.5%$0.584$0.584$0.51697,556
$0.550-0.067-10.8%$0.600$0.603$0.524216,589
$0.617-0.062-9.1%$0.650$0.702$0.616138,048
$0.679-0.103-13.2%$0.763$0.770$0.663525,562
$0.782-0.058-6.9%$0.752$0.870$0.750316,249
$0.840-0.100-10.6%$0.880$0.890$0.68017,366,069
$0.940-0.016-1.7%$0.910$0.956$0.90041,700
$0.956-0.164-14.6%$1.100$1.100$0.931173,600
$1.120-0.070-5.9%$1.200$1.200$1.100201,700
$1.190+0.030+2.6%$1.120$1.260$1.11059,400
$1.160-0.010-0.9%$1.110$1.200$1.045130,100
$1.170-0.060-4.9%$1.230$1.240$1.130270,600
$1.230-0.220-15.2%$1.110$1.330$1.11013,726,600
$1.450-0.100-6.5%$1.540$1.550$1.435160,100
$1.550-0.130-7.7%$1.680$1.680$1.470179,200
$1.680-0.460-21.5%$2.100$2.140$1.590248,600
$2.140-0.070-3.2%$2.190$2.270$2.100140,000
$2.210+0.020+0.9%$2.070$2.280$2.070150,900
$2.190-0.190-8.0%$2.310$2.380$2.180125,500
$2.380-0.100-4.0%$2.360$2.480$2.330128,300
$2.480-0.110-4.2%$2.420$2.490$2.300309,800
$2.590+0.080+3.2%$2.550$2.690$2.456237,600
$2.510-0.290-10.4%$2.550$2.750$2.480674,700
$2.800-0.030-1.1%$4.000$4.390$2.53052,286,800
$2.830+0.130+4.8%$2.630$3.118$2.410376,600
$2.700-0.330-10.9%$2.820$3.030$2.650219,900
$3.030-0.450-12.9%$3.340$3.499$2.790751,800
$3.480+0.750+27.5%$2.620$3.790$2.32010,751,400
$2.730+0.240+9.6%$2.450$3.290$2.2542,109,200
$2.490+0.110+4.6%$2.410$2.800$2.360536,100
$2.380+0.260+12.3%$2.138$2.450$2.133122,700
$2.120-0.110-4.9%$2.290$2.360$2.12056,900
$2.230+0.150+7.2%$2.160$2.440$2.120216,400
$2.080-0.030-1.4%$2.050$2.260$2.050114,700
$2.110+0.010+0.5%$2.120$2.170$2.05933,900
$2.100-0.160-7.1%$2.250$2.420$2.100146,600
$2.260+0.060+2.7%$2.190$2.390$2.170161,000
$2.200-0.200-8.3%$2.380$2.380$2.15876,500
$2.400-0.100-4.0%$2.260$2.470$2.220122,100
$2.500-0.270-9.7%$2.740$2.740$2.440159,500
$2.770-0.030-1.1%$2.900$2.989$2.72071,500
$2.800-0.320-10.3%$3.030$3.210$2.750139,300
$3.120+0.050+1.6%$3.020$3.239$2.700148,200
$3.070-0.500-14.0%$3.220$3.460$2.880291,900
$3.570+0.545+18.0%$2.800$3.870$2.800663,100
$3.025-0.050-1.6%$3.075$3.350$2.92520,899
$3.075-0.825-21.2%$3.800$3.875$2.92513,009
$3.900-0.075-1.9%$3.850$4.125$3.8255,642
$3.975-0.175-4.2%$3.625$4.075$3.50011,678
$4.150+1.075+35.0%$3.000$4.700$2.925175,607
$3.075+0.025+0.8%$2.975$3.300$2.8006,250
$3.050-0.300-9.0%$3.325$3.325$2.8757,999

Splits

3 splits since 2023 · NASDAQ:VBIO · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
1-for-17Consolidation
1-for-100Consolidation
Ticker
NASDAQ:VBIO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Valion Bio, Inc. news

Valion Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 27 in all · newest Nov 19, 2026 · oldest 2026
Calls
16 calls with a replay · 16 with a transcript · latest May 14, 2026
Decks
10 decks · latest Jan 20, 2026

Where Valion Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:VBIO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:VBIOBOATSUnited StatesUSD

Valuation

EV/sales 42.8× against a median of −4.2×: the highest of 3 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$16.34M USD
P/E
Loss
EV/sales
42.8×
EV/EBITDA
Negative EBITDA
Price/book
0.2×
Gross margin
8.4%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
4.1×
Beta vs S&P 500
1.11

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Valion Bio, Inc. · NASDAQ:VBIOUS$1.04MUS$16.34Mn/a42.8×n/a0.2×n/a4.1×1.11
Agentix Corp. · OTC:AGTXUS$1.35MUS$1.34Mn/an/an/an/an/an/a-0.73
Clearmind Medicine Inc. · NASDAQ:CMNDUS$1.33M−US$9.01Mn/an/an/a0.2×n/a0.0×0.29
Artelo Biosciences, Inc. · NASDAQ:ARTLUS$1.30MUS$1.34Mn/an/an/a0.2×n/a0.0×1.36
International Stem Cell Corporation · OTC:ISCOUS$1.28M−US$18.76M0.1×−2.0×n/a0.1×222.6%0.0×-0.52
SureNano Science Ltd · CSE:SUREUS$1.17MUS$672,321n/an/an/a0.3×n/a0.0×0.25
GeoVax Labs, Inc. · NASDAQ:GOVXUS$985,460−US$915,033n/an/an/a0.9×n/a0.2×1.47
Biodexa Pharmaceuticals plc · NASDAQ:BDRXUS$982,950−US$3.22Mn/an/an/a0.1×n/a0.0×1.01
Gabather AB · OMXSTO:GABAUS$919,514US$559,105n/an/an/a6.4×n/a0.0×n/a
ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2US$792,634−US$2.43Mn/a−6.5×n/a0.2×−935.9%0.0×n/a
Silexion Therapeutics Corp · NASDAQ:SLXNUS$790,001−US$3.60Mn/an/an/a0.3×n/a0.1×2.77
Median of the othersUS$1.08M−US$1.67M0.1×−4.2×0.2×−356.6%0.0×0.65

Team and board

Officers

OfficerRole
Dean ZikriaInterim CEO, Director
Lisa WolfChief Operating Officer & Chief Financial Officer
Melinda LackeyGeneral Counsel and SVP of Legal
Anna SzymanskaSVP, Quality and Regulatory Compliance
Brian W. O'MaraVP, Process Sciences and Manufacturing

Board

DirectorRole
Jared MalbinChair of the Board's Audit Committee, Independent Director
Christina ValauriIndependent Director
Dean ZikriaInterim CEO, Director
Michael K. HandleyDirector
Thomas JensenDirector

Events

Calls

CallWhenStatus
Valion Bio (NASDAQ:VBIO) Q1 2026 Earnings CallThu, May 14, 2026 · 5:00 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q4 2025 Earnings CallWed, Mar 25, 2026 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q3 2025 Earnings CallFri, Nov 14, 2025 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q2 2025 Earnings CallThu, Aug 14, 2025 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q1 2025 Earnings CallThu, May 15, 2025 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings CallFri, Mar 21, 2025 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings CallThu, Nov 14, 2024 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q1 2024 Earnings CallWed, May 15, 2024 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q4 2023 Earnings CallMon, Mar 25, 2024 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q3 2023 Earnings CallTue, Nov 14, 2023 · 4:30 PM ETReplay
All 16 calls
CallWhenStatus
Tivic Health Systems, Inc. (TIVC) Q2 2023 Earnings CallMon, Aug 14, 2023 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q1 2023 Earnings CallMon, May 15, 2023 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q4 2022 Earnings CallFri, Mar 31, 2023 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q3 2022 Earnings CallMon, Nov 14, 2022 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q2 2022 Earnings CallMon, Aug 15, 2022 · 4:30 PM ETReplay
Tivic Health Systems, Inc. (TIVC) Q1 2022 Earnings CallMon, May 16, 2022 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 20, 2026
Q2 2026Aug 14, 2026+7.0%
Q1 2026May 15, 2026−7.6%
Q3 2025Nov 17, 2025−1.6%
Q2 2025Aug 15, 2025−5.4%
Q1 2025May 15, 2025−1.2%
Q4 2024Mar 24, 2025−9.6%
Q3 2024Nov 15, 2024−27.8%
Q2 2024Aug 15, 2024+6.1%
Q1 2024May 16, 2024−6.4%
All 18 quarters
QuarterResultsShare move
Q4 2023Mar 26, 2024−17.9%
Q3 2023Nov 14, 2023 · After close−13.8%
Q2 2023Aug 14, 2023 · After close−7.5%
Q1 2023May 16, 2023−32.6%
Q4 2022Mar 31, 2023 · Before open−13.2%
Q3 2022Nov 14, 2022 · Before open0.0%
Q2 2022Aug 15, 2022 · After close−3.9%
Q1 2022Jun 1, 2022+7.7%

Open Events

Decks

Open Decks

IPO

Went public as Tivic Health Systems, Inc. Priced at US$5.00 a share on Nov 10, 2021.

Price
US$5.00 a share
Shares offered
3,000,000 shares of common stock
Offering size
US$15 million
Underwriters' option
Up to 450,000 more shares
Listing
TIVC on the Nasdaq Capital Market
Underwriter
ThinkEquity
Shares delivered
On or about Nov 15, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMay 14, 2021
Filed publiclyAug 3, 2021
Amended 4 timesNewest Oct 29, 2021
Shares registered with an exchangeNov 10, 2021
Declared effective by the SECNov 10, 2021
Final prospectus, with the priceNov 12, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Nov 12, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017FY2016FY2015
Revenue382.0K780.0K1.18M1.84M1.26M860.0K420.0K102.4K163.4K248.3K
Cost of revenue350.0K778.0K889.0K1.54M1.29M1.09M713.0K77.9K108.3K149.5K
Gross profit32.0K2.00K287.0K299.0K-38.0K-233.0K-293.0K24.5K55.1K98.9K
Research and development3.13M1.31M1.66M1.73M878.0K768.0K986.0K1.90M894.0K613.1K
Selling, general and administrative4.77M3.16M4.75M5.88M1.93M2.68M2.52M2.63M2.23M
Operating income-7.90M-4.48M-8.24M-10.1M-5.63M-3.32M-3.64M-4.40M-3.47M-2.74M
Depreciation and amortization5.00K3.00K8.00K10.0K8.00K8.00K4.00K87.8K1.75M2.60M
EBITDA-7.89M-4.47M-8.24M-10.1M-5.63M-3.31M-3.64M-4.31M-1.72M-141.0K
Interest expense146.0K01.82M423.0K443.0K1.01K363
Income before tax8.90M5.70M-8.24M-10.1M-8.49M-3.64M-4.15M-4.31M-5.22M-141.3K
Income tax002.00K
Net income-8.88M-5.66M-8.24M-10.1M-8.49M-3.64M-4.15M-4.31M-5.22M-141.3K
Earnings per share, basic-7.84-19.68-176.80-104.32-2.43-667.71-761.10-0.19-0.38-0.02
Earnings per share, diluted-19.68-176.80-104.32-2.43

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017FY2016FY2015
Cash and equivalents12.6M2.00M3.40M3.52M13.0M1.04M2.31M656.3K1.15M95.4K
Receivables1.00K69.0K174.0K107.0K92.0K52.0K13.0K13.8K19.2K30.4K
Inventory0319.0K756.0K863.0K429.0K241.0K475.0K6.47K
Current assets13.0M2.64M4.65M5.31M14.3M1.50M2.97M675.8K1.18M134.8K
Property, plant and equipment12.6M2.00K122.0K12.0K11.0K
Goodwill3.46M0
Total assets31.6M2.81M5.16M5.88M15.0M1.53M3.02M675.8K1.18M134.8K
Accounts payable264.0K125.0K713.0K1.32M789.0K370.0K369.0K
Current liabilities646.0K272.0K1.40M1.88M1.22M1.27M653.0K353.5K800.6K653.0K
Long-term debt6.45M
Total debt6.45M369.0K530.0K708.0K1.47M
Total liabilities7.44M272.0K1.58M2.25M1.76M2.71M653.0K353.5K800.6K653.0K
Shareholders' equity16.8M2.54M3.58M3.63M13.3M-1.18M2.37M322.3K374.4K-518.2K
Shares outstanding2.53M556.9K86.2K96.8K9.72M5.45K5.45K23.1M13.6M7.54M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017FY2016FY2015
Cash from operations-7.00M-5.72M-8.51M-8.92M-5.61M-3.03M-3.67M-2.89M-1.38M-1.69M
Capital spending-38.0K0-118.0K-11.0K00-31.0K000
Free cash flow-7.04M-5.72M-8.63M-8.93M-5.61M-3.03M-3.70M-2.89M-1.38M-1.69M
Cash from investing-705.0K0-118.0K-11.0K-31.0K
Cash from financing18.3M4.33M8.51M-528.0K17.5M1.76M5.55M2.39M2.44M1.39M
Change in cash10.6M-1.39M-122.0K-9.46M11.9M-1.27M2.31M-496.5K1.06M-294.3K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 16, 2026Management or board changeSEC
NT 10-Q · Late filing noticeNov 16, 2026Explanation requestSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
8-K · Current reportNov 9, 2026Material contractSEC
8-K · Current reportNov 5, 2026Management or board changeSEC
8-K · Current reportNov 2, 2026Management or board changeSEC
8-K · Current reportOct 29, 2026Current reportSEC
8-K · Current reportOct 27, 2026Material contractSEC
8-K · Current reportOct 26, 2026Current reportSEC
8-K · Current reportOct 22, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveOct 21, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveOct 21, 2026Other filingsSEC
424B3 · ProspectusOct 20, 2026Offer documentSEC
S-3 · Registration statementOct 16, 2026Offer documentSEC
DEF 14A · Proxy statementOct 16, 2026Meeting noticeSEC
8-K · Current reportOct 15, 2026Current reportSEC
8-K · Current reportOct 14, 2026Current reportSEC
8-K · Current reportOct 8, 2026Material contractSEC
S-3 · Registration statementOct 7, 2026Offer documentSEC
8-K · Current reportOct 6, 2026Current reportSEC
DRS · Draft registration statementOct 5, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementOct 5, 2026Meeting noticeSEC
8-K · Current reportOct 1, 2026Current reportSEC
4 · Change in ownershipSep 24, 2026Insider tradeSEC
4 · Change in ownershipSep 24, 2026Insider tradeSEC
8-K · Current reportSep 23, 2026Management or board changeSEC
3 · Initial statement of ownershipSep 17, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 4, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 3, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 2, 2026Big-stake noticeSEC
8-K · Current reportSep 1, 2026Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 27, 2026Big-stake noticeSEC
8-K · Current reportAug 27, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 24, 2026Big-stake noticeSEC
RW · Request to withdraw a registrationAug 24, 2026Other filingsSEC
8-K/A · Current report, amendedAug 20, 2026Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 19, 2026Big-stake noticeSEC
8-K · Current reportAug 17, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveAug 13, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 11, 2026Big-stake noticeSEC
8-K · Current reportAug 6, 2026Material contractSEC
SCHEDULE 13D · Big-stake noticeAug 3, 2026Big-stake noticeSEC
DEF 14A · Proxy statementJul 17, 2026Meeting noticeSEC
S-1 · Registration statementJul 17, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2026Big-stake noticeSEC
8-K · Current reportJul 14, 2026Current reportSEC
PRE 14A · Preliminary proxy statementJul 7, 2026Meeting noticeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
8-K · Current reportJun 18, 2026FinancingSEC
S-8 · Registration statement for employee plansJun 5, 2026Offer documentSEC
S-8 · Registration statement for employee plansJun 5, 2026Offer documentSEC
8-K · Current reportJun 3, 2026Management or board changeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 8, 2026Big-stake noticeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 4, 2026Insider tradeSEC
8-K · Current reportMay 4, 2026Management or board changeSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
8-K · Current reportApr 23, 2026Current reportSEC
PRE 14A · Preliminary proxy statementApr 20, 2026Meeting noticeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 16, 2026Other filingsSEC
424B3 · ProspectusApr 15, 2026Offer documentSEC
CORRESP · Letter to the SECApr 13, 2026Other filingsSEC
DRS · Draft registration statementApr 13, 2026Offer documentSEC
S-1 · Registration statementApr 13, 2026Offer documentSEC
UPLOAD · Letter from the SECApr 9, 2026Other filingsSEC
DRS · Draft registration statementApr 6, 2026Offer documentSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 25, 2026ResultsSEC
8-K · Current reportMar 20, 2026Current reportSEC
4 · Change in ownershipMar 19, 2026Insider tradeSEC
8-K · Current reportMar 13, 2026Material contractSEC
8-K · Current reportMar 11, 2026Meeting outcomeSEC
8-K · Current reportMar 4, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeFeb 27, 2026Big-stake noticeSEC
8-K/A · Current report, amendedFeb 23, 2026Current reportSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
DEFA14A · Additional proxy materialFeb 9, 2026Meeting noticeSEC
8-K · Current reportFeb 9, 2026Material contractSEC
424B3 · ProspectusJan 20, 2026Offer documentSEC
424B3 · ProspectusJan 20, 2026Offer documentSEC
8-K · Current reportJan 20, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJan 20, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveJan 20, 2026Other filingsSEC
CORRESP · Letter to the SECJan 14, 2026Other filingsSEC
CORRESP · Letter to the SECJan 14, 2026Other filingsSEC
DEF 14A · Proxy statementJan 9, 2026Meeting noticeSEC
UPLOAD · Letter from the SECJan 5, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 5, 2026Other filingsSEC
DDec 29, 2025Other filingsSEC
DDec 29, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementDec 29, 2025Meeting noticeSEC
S-3 · Registration statementDec 29, 2025Offer documentSEC
S-3 · Registration statementDec 29, 2025Offer documentSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
424B3 · ProspectusDec 12, 2025Offer documentSEC
424B3 · ProspectusDec 12, 2025Offer documentSEC
8-K · Current reportDec 11, 2025Acquisition or disposalSEC
8-K · Current reportNov 18, 2025Current reportSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
8-K · Current reportNov 13, 2025Current reportSEC
424B3 · ProspectusNov 6, 2025Offer documentSEC
S-3 · Registration statementOct 17, 2025Offer documentSEC
8-K · Current reportOct 15, 2025Management or board changeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
1-A-WSep 17, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 8, 2025Other filingsSEC
424B3 · ProspectusSep 5, 2025Offer documentSEC
CORRESP · Letter to the SECSep 3, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 3, 2025Other filingsSEC
S-3 · Registration statementAug 29, 2025Offer documentSEC
8-K · Current reportAug 27, 2025Current reportSEC
4/A · Change in ownership, amendedAug 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedAug 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedAug 22, 2025Insider tradeSEC
8-K · Current reportAug 20, 2025Current reportSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
EFFECT · Notice that a registration is effectiveAug 13, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 13, 2025Other filingsSEC
424B3 · ProspectusAug 12, 2025Offer documentSEC
424B3 · ProspectusAug 12, 2025Offer documentSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
CORRESP · Letter to the SECAug 8, 2025Other filingsSEC
CORRESP · Letter to the SECAug 8, 2025Other filingsSEC
S-3 · Registration statementAug 8, 2025Offer documentSEC
S-3 · Registration statementAug 8, 2025Offer documentSEC
UPLOAD · Letter from the SECAug 5, 2025Other filingsSEC
DRS · Draft registration statementAug 4, 2025Offer documentSEC
DRSLTR · Letter to the SEC with a draftAug 4, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 31, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 31, 2025Other filingsSEC
424B3 · ProspectusJul 30, 2025Offer documentSEC
CORRESP · Letter to the SECJul 28, 2025Other filingsSEC
CORRESP · Letter to the SECJul 25, 2025Other filingsSEC
S-1/A · Registration statement, amendedJul 25, 2025Offer documentSEC
S-8 · Registration statement for employee plansJul 25, 2025Offer documentSEC
S-8 · Registration statement for employee plansJul 25, 2025Offer documentSEC
DRS · Draft registration statementJul 25, 2025Offer documentSEC
8-K/A · Current report, amendedJul 25, 2025Material contractSEC
UPLOAD · Letter from the SECJul 9, 2025Other filingsSEC
8-K · Current reportJul 7, 2025Management or board changeSEC
CORRESP · Letter to the SECJun 26, 2025Other filingsSEC
8-K · Current reportJun 25, 2025Material contractSEC
8-K · Current reportJun 25, 2025Current reportSEC
UPLOAD · Letter from the SECJun 17, 2025Other filingsSEC
CORRESP · Letter to the SECJun 6, 2025Other filingsSEC
S-1 · Registration statementJun 6, 2025Offer documentSEC
ARS · Annual report to shareholdersJun 2, 2025Annual reportSEC
DEF 14A · Proxy statementJun 2, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementMay 23, 2025Meeting noticeSEC
8-K · Current reportMay 22, 2025Current reportSEC
UPLOAD · Letter from the SECMay 21, 2025Other filingsSEC
8-K · Current reportMay 20, 2025Current reportSEC
DRS · Draft registration statementMay 15, 2025Offer documentSEC
DRSLTR · Letter to the SEC with a draftMay 15, 2025Other filingsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
8-K · Current reportMay 14, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveMay 14, 2025Other filingsSEC
424B3 · ProspectusMay 13, 2025Offer documentSEC
CORRESP · Letter to the SECMay 9, 2025Other filingsSEC
S-1 · Registration statementMay 9, 2025Offer documentSEC
UPLOAD · Letter from the SECMay 8, 2025Other filingsSEC
DRS · Draft registration statementMay 2, 2025Offer documentSEC
DRSLTR · Letter to the SEC with a draftMay 2, 2025Other filingsSEC
8-K · Current reportMay 2, 2025Material contractSEC
8-K · Current reportApr 22, 2025Current reportSEC
8-K · Current reportApr 14, 2025Current reportSEC
424B5 · ProspectusApr 14, 2025Offer documentSEC
8-K · Current reportApr 10, 2025Current reportSEC
8-K · Current reportApr 3, 2025FinancingSEC
10-K · Annual reportMar 21, 2025Annual reportSEC
8-K · Current reportMar 21, 2025ResultsSEC
8-K · Current reportMar 6, 2025Current reportSEC
8-K · Current reportMar 5, 2025Current reportSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 24, 2025Insider tradeSEC
8-K · Current reportFeb 24, 2025Management or board changeSEC
8-K · Current reportFeb 12, 2025Material contractSEC
8-K · Current reportFeb 5, 2025Meeting outcomeSEC
DEF 14A · Proxy statementJan 3, 2025Meeting noticeSEC
8-K · Current reportJan 3, 2025Current reportSEC
8-K · Current reportDec 23, 2024Current reportSEC
PRE 14A · Preliminary proxy statementDec 23, 2024Meeting noticeSEC

This page holds 200 of 407 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Valion Bio, Inc.’s releases

Common shares
2,155,637
Fully diluted
2,155,637

Fully diluted

LineShares
Common shares2,155,637

Share count over time

CountShares
Nov 22, 20262,155,637
Aug 27, 2026

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund50,3420.23%US$38,562May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Murchinson Ltd.9.99%440KJun 8, 2026Schedule 13G
3i, LP9.90%3.33MAug 25, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Christina Valauri
Other companies: Precipio, Inc. (Director · Since at least Jan 2, 2024)
Director · Since at least Jul 1, 2024
Lisa Wolf
Other companies: Resonant Inc (Chief Accounting Officer · May 14, 2021 – Mar 28, 2022 · Past)
Chief Operating Officer & Chief Financial Officer · Since at least Oct 1, 2024
Thomas Jensen
Other companies: Allarity Therapeutics, Inc. (CEO · Since at least Dec 20, 2021)
Director · Since at least Aug 27, 2026
Anna SzymanskaSVP, Quality and Regulatory Compliance · Since at least Nov 20, 2026
Blake GurfeinChief Scientific Officer · Nov 10, 2021 – Dec 18, 2024 · Past
Brian W. O'MaraVP, Process Sciences and Manufacturing · Since at least Nov 20, 2026
Dean ZikriaInterim CEO, Director · Since at least Aug 6, 2025
Jared MalbinDirector · Since at least Aug 27, 2026
Jennifer ErnstChief Executive Officer, Director · Since at least Nov 10, 2021
Melinda LackeyGeneral Counsel and SVP of Legal · Since at least May 4, 2026
All 11 people
PersonSeat
Michael K. HandleyDirector · Since at least Aug 6, 2025

Open People

Log in to ask 6ix AI your own questions about Valion Bio, Inc.